Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer

Growth Hormone & IGF Research - Tập 69 - Trang 101533 - 2023
Rachel Barker1, Kalina Biernacka1, Georgina Kingshott1, Alex Sewell2, Paida Gwiti2,3, Richard M. Martin4,5, J. Athene Lane6, Lucy McGeagh7, Anthony Koupparis8, Edward Rowe8, Jon Oxley2, Claire M. Perks1, Jeff M.P. Holly1
1IGF & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Learning & Research Building, Southmead Hospital, Bristol BS10 5NB, UK
2Department of Cellular Pathology, North Bristol NHS Trust, Southmead Hospital, Bristol BS10 5NB, UK
3Department of Pathology, North West Anglia NHS Foundation Trust, Peterborough PE3 9GZ, UK
4Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
5National Institute for Health Research, Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Biomedical Research Unit Offices, University Hospitals Bristol Education Centre, Dental Hospital, Lower Maudlin Street, Bristol BS1 2LY, UK
6Bristol Trials Centre, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
7Supportive Cancer Care Research Group, Faculty of Health and Life Sciences, Oxford Institute of Nursing, Midwifery and Allied Health Research, Oxford Brookes University, Jack Straws Lane, Marston, Oxford OX3 0FL, UK
8Department of Urology, Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, UK

Tài liệu tham khảo

Dadaev, 2018, Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants, Nat. Commun., 9, 2256, 10.1038/s41467-018-04109-8

Shui, 2014, Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium, Eur. Urol., 65, 1069, 10.1016/j.eururo.2013.12.058

Helfand, 2015, Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases, Hum. Genet., 134, 439, 10.1007/s00439-015-1534-9

Hazelett, 2014, Comprehensive functional annotation of 77 prostate cancer risk loci, PLoS Genet., 10, 10.1371/journal.pgen.1004102

Guo, 2016, Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer, Nat. Genet., 48, 1142, 10.1038/ng.3637

Jia, 2009, Functional enhancers at the gene-poor 8q24 cancer-linked locus, PLoS Genet., 5, 10.1371/journal.pgen.1000597

Mazrooei, 2019, Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors, Cancer Cell, 36, 674, 10.1016/j.ccell.2019.10.005

Fraser, 2017, Genomic hallmarks of localized, non-indolent prostate cancer, Nature., 541, 359, 10.1038/nature20788

Dai, 2017, Androgen signaling in prostate cancer, Cold Spring Harb. Perspect. Med., 7, 10.1101/cshperspect.a030452

Fei, 2019, Deciphering essential cistromes using genome-wide CRISPR screens, Proc. Natl. Acad. Sci. U. S. A., 116, 25186, 10.1073/pnas.1908155116

Ohlsson, 2001, CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease, Trends Genet., 17, 520, 10.1016/S0168-9525(01)02366-6

Guastafierro, 2008, CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery, J. Biol. Chem., 283, 21873, 10.1074/jbc.M801170200

Phillips, 2009, CTCF: master weaver of the genome, Cell, 137, 1194, 10.1016/j.cell.2009.06.001

Ong, 2014, CTCF: an architectural protein bridging genome topology and function, Nat. Rev. Genet., 15, 234, 10.1038/nrg3663

Carroll, 2005, Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1, Cell, 122, 33, 10.1016/j.cell.2005.05.008

Lupien, 2008, FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription, Cell, 132, 958, 10.1016/j.cell.2008.01.018

Zhang, 2019, An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells, Genome Res., 29, 223, 10.1101/gr.230243.117

Gao, 2005, Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation, Development., 132, 3431, 10.1242/dev.01917

Prins, 2008, Molecular signaling pathways that regulate prostate gland development, Differentiation., 76, 641, 10.1111/j.1432-0436.2008.00277.x

Yang, 2015, Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer, Genes Dis., 2, 144, 10.1016/j.gendis.2015.01.003

Cancer Genome Atlas Research N, 2015, The molecular taxonomy of primary prostate cancer, Cell., 163, 1011, 10.1016/j.cell.2015.10.025

Rhie, 2019, A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome, Nat. Commun., 10, 4154, 10.1038/s41467-019-12079-8

Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat. Genet., 44, 685, 10.1038/ng.2279

Augello, 2011, FOXA1: master of steroid receptor function in cancer, EMBO J., 30, 3885, 10.1038/emboj.2011.340

Gao, 2003, The role of hepatocyte nuclear factor-3 alpha (Forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes, Mol. Endocrinol., 17, 1484, 10.1210/me.2003-0020

Jin, 2014, Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program, Nat. Commun., 5, 3972, 10.1038/ncomms4972

Gao, 2019, Forkhead domain mutations in FOXA1 drive prostate cancer progression, Cell Res., 29, 770, 10.1038/s41422-019-0203-2

Travis, 2016, A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk, Cancer Res., 76, 2288, 10.1158/0008-5472.CAN-15-1551

Bonilla, 2016, Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: genetic variants as instruments for circulating levels, Int. J. Cancer, 139, 1520, 10.1002/ijc.30206

Holly, 2020, The role of insulin-like growth factors in the development of prostate cancer, Expert. Rev. Endocrinol. Metab., 15, 237, 10.1080/17446651.2020.1764844

Szabo, 2000, Maternal-specific footprints at putative CTCF sites in the H19 imprinting control region give evidence for insulator function, Curr. Biol., 10, 607, 10.1016/S0960-9822(00)00489-9

Kingshott, 2021, Alteration of metabolic conditions impacts the regulation of IGF-II/H19 imprinting status in prostate cancer, Cancers (Basel), 13, 10.3390/cancers13040825

Damaschke, 2017, Loss of Igf2 gene imprinting in murine prostate promotes widespread neoplastic growth, Cancer Res., 77, 5236, 10.1158/0008-5472.CAN-16-3089

Potter, 2012, Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity, J. Cell. Biochem., 113, 110, 10.1002/jcb.23333

Mansor, 2020, IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells, Oncotarget, 11, 2543, 10.18632/oncotarget.27650

Uzoh, 2009, PTEN-mediated pathways and their association with treatment-resistant prostate cancer, BJU Int., 104, 556, 10.1111/j.1464-410X.2009.08411.x

Hackshaw-McGeagh, 2019, Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer, BMJ Open, 9, 10.1136/bmjopen-2019-029480

Dean, 2014, Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer, Am. J. Clin. Pathol., 141, 323, 10.1309/AJCPR11DEAYPTUSL

Whitington, 2016, Gene regulatory mechanisms underpinning prostate cancer susceptibility, Nat. Genet., 48, 387, 10.1038/ng.3523

Chen, 2015, Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci, Prostate., 75, 1264, 10.1002/pros.23008

Shan, 2019, CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer, J. Cell. Mol. Med., 23, 3130, 10.1111/jcmm.14138

Hoflmayer, 2020, Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer, Mol. Oncol., 14, 129, 10.1002/1878-0261.12597

Jain, 2011, High-level expression of forkhead-box protein A1 in metastatic prostate cancer, Histopathology., 58, 766, 10.1111/j.1365-2559.2011.03796.x

Sahu, 2011, Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer, EMBO J., 30, 3962, 10.1038/emboj.2011.328

Pandini, 2005, Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells, Cancer Res., 65, 1849, 10.1158/0008-5472.CAN-04-1837

Pandini, 2009, Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway, Ann. N. Y. Acad. Sci., 1155, 263, 10.1111/j.1749-6632.2009.04361.x

Jin, 2013, Androgen receptor-independent function of FoxA1 in prostate cancer metastasis, Cancer Res., 73, 3725, 10.1158/0008-5472.CAN-12-3468

Taslim, 2012, Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF, Nucleic Acids Res., 40, 4754, 10.1093/nar/gks139

Qiu, 2008, A complex deoxyribonucleic acid looping configuration associated with the silencing of the maternal Igf2 allele, Mol. Endocrinol., 22, 1476, 10.1210/me.2007-0474

Verona, 2004, Role of H19 3′ sequences in controlling H19 and Igf2 imprinting and expression, Genomics., 84, 59, 10.1016/j.ygeno.2003.12.001

Thông tin
Thông tin xuất bản

Growth Hormone & IGF Research

Tập 69

101533

Thông tin tác giả